Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in ALK+ NSCLC Post-Crizotinib
NCT02094573Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jun 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by ARIAD Pharmaceuticals, Inc.. Started Jun 2014; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02094573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094573.